Mind Medicine

MindMed in its US$100 million At-the-Market Program


Mind Medicine


US$100 million


Capital Markets

Date Closed

May 2022


Pharmaceuticals and Life Sciences

Lead Office



On May 16, 2022, Mind Medicine (MindMed) announced it had implemented a US$100 million at-the-market (ATM) equity offering program. Distributions of the shares under the ATM Program will be made pursuant to the terms of an equity offering sales agreement entered with agents Cantor Fitzgerald & Co. and Oppenheimer & Co. Inc.

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The Company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

Osler, Hoskin & Harcourt LLP acted as Canadian counsel to MindMed with a team including Trevor Scott, Minji Park, Natalie Holtby (Corporate), Timothy Hughes and James Chang (Tax).